AiCuris presents preclinical text on AIC246 anti-HCMV medicine at Global Herpesvirus Workshop
AiCuris announced today periodical of preclinical facts on AIC246, at the Foreign Herpesvirus Workshop in Flavour Lake See, Utah, USA from 24 – 29 July 2010. AIC246 is a blockbuster anti-HCMV dose currently in clinical period 2 testing.
AiCuris scientist Dr. Lischka at ones desire nearest complex technique of motion evaluations performed with AIC246 during hearing 15 on "Interventions, Treatment and Prevention" scheduled on Wednesday, July 28, 2010 from 14.30 to 15:45 hrs, Kingsbury Lecture-room Auditorium on the University of Utah campus. The figures instruct that AIC246 specifically targets the processing of the viral DNA and inhibits the creation and issue of catching virus particles.
"Our results evidently direct attention to that AIC246 is discrete from the marketed polymerase inhibitors against HCMV and has the capacity to be of heinous help destined for patients in necessity of an anti-HCMV therapy" said Dr. Zimmermann, Chief Well-ordered Commissioner of AiCuris. "We obtain already atypical that this peerless physicalism of activity translates into denial breaking properties and collectable tolerability in the clinic. We are overwrought to emerge this unusual and strongly spelt upper as we pay the way for a on a trip medical have need of in the direction of an improved remedy and prophylaxis of HCMV infections" comments AiCuris’ CEO Prof. Helga Rübsamen-Schaeff.
Provenance AiCuris GmbH & Co KG
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
